Who Owns STAAR Surgical Company?

Who Owns STAAR Surgical Company?

STAAR Surgical Company, a leader in implantable lenses for vision correction, has a history shaped by its founders and evolving ownership. Established in 1982, the company has grown significantly, driven by innovation in ophthalmic surgery.

Understanding STAAR Surgical's ownership is key to grasping its market influence and strategic direction in the vision correction sector. The company's commitment to 'Evolution in Visual Freedom' through its ICLs remains central to its operations.

As of December 2024, STAAR Surgical reported net sales of $313.9 million, with its ICL products, including the Visian ICL and EVO family, accounting for approximately 100% of these sales. This focus highlights the importance of its core offerings, such as the STAAR Surgical BCG Matrix, in its financial performance and market position.

STAAR Surgical Company's journey began in early 1982 as a partnership between Tom Waggoner and Dr. Thomas Mazzocco. Their initial focus was to commercialize Dr. Mazzocco's innovative concept for a foldable intraocular lens (IOL), aiming to provide a less invasive option for cataract surgery patients compared to traditional rigid lenses.

Founding Partnership

Tom Waggoner and Dr. Thomas Mazzocco established STAAR Surgical in 1982. Their collaboration was driven by Dr. Mazzocco's pioneering foldable intraocular lens (IOL) technology.

Initial Investment

The founders jointly contributed $250,000 at the company's inception. This capital was allocated for the crucial development and FDA approval processes for their IOLs.

Early Financial Challenges

By early 1983, the company faced significant debt, necessitating Waggoner's pursuit of venture capital. He noted a substantial gap between his funding needs and investor offers.

Navigating FDA Approval

With FDA approval for their IOLs not expected until 1987, the company incurred substantial monthly expenses. Maintaining consistent revenue was paramount for survival during this period.

Initial Public Offering (IPO)

STAAR Surgical successfully completed its initial public offering (IPO) in 1983. This move was essential for securing the external capital required for ongoing research and development.

Early Ownership Structure

While specific details on early equity splits and investor allocations beyond the founders are limited, the IPO highlights the company's early reliance on external funding to support its growth and regulatory efforts.

The early years of STAAR Surgical were characterized by the founders' commitment to innovation and the significant hurdles of medical device development. Tom Waggoner, in his early thirties, was driven to bring Dr. Thomas Mazzocco's foldable intraocular lens (IOL) to market, a significant advancement over existing rigid lenses. This endeavor required substantial capital, not only for product development but also for the rigorous FDA approval process, which was a lengthy and costly undertaking. The company's initial public offering (IPO) in 1983 was a critical step in securing the necessary funding to sustain operations and continue its research and development, especially given the high monthly expenses and the projected timeline for regulatory clearance. Understanding this early reliance on external capital provides context for the subsequent evolution of STAAR Surgical ownership, as detailed in analyses of its Competitors Landscape of STAAR Surgical.

Complete STAAR Surgical Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

STAAR Surgical Company, established as a public entity in 1983, has witnessed a significant transformation in its ownership landscape, characterized by a growing influence of institutional investors. This evolution reflects broader trends in the investment community and the company's performance.

The ownership structure of STAAR Surgical Company demonstrates a strong presence of institutional investors, signaling confidence in the company's market standing. As of March 31, 2025, these entities collectively held a substantial portion of the company's shares, with Vanguard Group Inc. and BlackRock Fund Advisors leading the way. This institutional backing is particularly noteworthy given the company's financial performance, which saw net sales of $313.9 million for the fiscal year ended December 27, 2024, with nearly all sales generated from implantable Collamer Lens (ICL) products. The majority of its revenue, approximately 94% in fiscal 2024, originated from international markets, highlighting its global operational footprint and the Revenue Streams & Business Model of STAAR Surgical.

STAAR Surgical Ownership Overview

Institutional investors play a dominant role in STAAR Surgical's ownership. Their significant holdings underscore a belief in the company's strategic direction and market potential.

• STAAR Surgical became a public company in 1983.
• Institutional investors held 106.16% of outstanding shares by March 31, 2025.
• Key institutional shareholders include Vanguard Group Inc. and BlackRock Fund Advisors.
• The company reported net sales of $313.9 million for the fiscal year ended December 27, 2024.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

As of April 24, 2025, STAAR Surgical Company's Board of Directors comprises seven individuals: Arthur C. Butcher, Stephen C. Farrell, Wei Jiang, Louis E. Silverman, Aimee S. Weisner, Elizabeth Yeu, M.D., and Lilian Y. Zhou. Stephen C. Farrell also holds the position of CEO.

The company's voting structure is based on a one-share-one-vote principle, meaning each share of common stock typically grants its holder one vote. Shareholders exercise their voting rights by submitting proxies or voting instructions, particularly for significant corporate decisions such as the election of directors. The annual meeting of shareholders for 2025 was scheduled for June 18, 2025, with shareholders of record as of April 22, 2025, eligible to participate. Aimee S. Weisner, a director since 2022, will not seek re-election at this meeting, leading to a planned reduction in the board's size from seven to six members.

STAAR Surgical Company Ownership and Governance

Understanding STAAR Surgical ownership is key for investors. The company's governance structure ensures that decisions are made with shareholder interests in mind.

• STAAR Surgical is a publicly traded company, meaning its stock is available for purchase by the general public.
• The majority of STAAR Surgical shareholders are institutional investors, such as mutual funds and pension funds.
• Individual investors can also be STAAR Surgical shareholders, contributing to the overall ownership breakdown.
• The board of directors plays a crucial role in overseeing the company's operations and strategy, aligning with the Mission, Vision & Core Values of STAAR Surgical.

STAAR Surgical Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

STAAR Surgical Company has seen shifts in its ownership structure over the past few years, marked by strategic financial decisions and leadership changes. These developments are influencing how the company is held and managed, reflecting broader market dynamics and internal adjustments. Understanding these trends is key for comprehending the current STAAR Surgical ownership landscape.

Recent strategic moves by STAAR Surgical include a $30 million share repurchase authorization in May 2025, aimed at enhancing shareholder value. Leadership has also been refreshed, with Stephen C. Farrell appointed CEO in February 2025 and Deborah Andrews joining as CFO in June 2025, alongside a broader leadership realignment in March 2025. These changes occur amidst financial headwinds, with a reported net loss of $(20.2) million for fiscal year 2024, a contrast to the prior year's net income of $21.3 million. The first quarter of 2025 saw net sales drop by 45% year-over-year to $42.6 million, largely due to inventory consumption by distributors in China, though sales outside China grew by 9%. The company incurred significant restructuring charges of $22.7 million in Q1 2025 as part of efforts to reduce annualized SG&A expenses. The stock price has also seen a substantial decrease, trading at $19.20 per share on July 25, 2025, down from $41.52 on July 29, 2024. The company anticipates a return to normalized sales in China by Q3 2025 and is bolstering production in Switzerland.

Institutional Investor Activity

Institutional investors increased their stake in STAAR Surgical to 106.16% by March 2025. This indicates a growing confidence from large financial entities in the company's future prospects. Understanding the Target Market of STAAR Surgical can provide context for this trend.

Leadership and Strategy

New leadership appointments in early 2025 signal a strategic pivot. The company is focused on cost control and expanding production to navigate market challenges and tariff concerns.

Financial Performance and Outlook

Despite a net loss in 2024 and a sales decline in Q1 2025, the company projects a stabilization of sales in China by Q3 2025. Efforts are underway to improve the cost structure and return to historical growth patterns.

Stock Performance and Shareholder Value

The share price has experienced a significant downturn, with a 53.76% decrease noted between July 2024 and July 2025. The recent share repurchase authorization aims to address this by reducing outstanding shares and potentially boosting per-share value for STAAR Surgical shareholders.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE